THE JOURNAL OF
CLINICAL PSYCHIATRY
THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

Author(s): Le-Ben Wan, MD, PhD; Cara F. Levitch, BA; Andrew M. Perez, MD; Jess W. Brallier, MD; Dan V. Iosifescu, MD, MMSc; Lee C. Chang, MD; Alexandra Foulkes, MS; Sanjay J. Mathew, MD; Dennis S. Charney, MD; and James W. Murrough, MD

DOI Number: 10.4088/JCP.13m08852

List of Supplementary Material for the article

1. eTable 1 — Long-Term Follow-Up Data Summary
2. eFigure 1 — Lack of Correlation between Acute Dissociation and Subsequent Antidepressant Response
3. eFigure 2 — Distribution of Responses to Ketamine Acceptability Questionnaire
4. eAppendix 1 — Adapted from Perry EB Jr, Cramer JA, Cho HS, et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl). 2007;192(2):253-260.

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary eTable 1. Long-Term Follow-Up Data Summary

Item	Yes, Count	Notes
Physical Problems	0	-
Emotional/Psychological Problems	1	Resolved 1 month post-study
Cravings for Ketamine	0	-
Use of Ketamine	0	-
Cravings for Other Substances	0	-
Increased Use of Other Substances	0	-

n=46, average follow-up time 2.9±0.2 years

A.



B.



Supplementary eFigure 1. Lack of Correlation between Acute Dissociation and Subsequent Antidepressant Response. Scatter plots showing change in CADSS score at 40 min post-infusion versus ketamine responder status (A; r=0.14; p=0.20) and change in MADRS score (B; r=0.09; p=0.34) at 24 hrs post-infusion. Results are based on 84 unique subjects.



Supplementary eFigure 2. Distribution of Responses to Ketamine Acceptability Questionnaire. Graph depicts frequency histogram of responses to a questionnaire assessing patient report of the potential acceptability of ketamine as a treatment for depression. 1 = not at all acceptable, 3 = somewhat acceptable, and 5 = very acceptable. n=46 subjects re-contacted for long-term follow-up.

eAppendix 1. Adapted from Perry EB Jr, Cramer JA, Cho HS, et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl). 2007;192(2):253-260.

- Since your participation in the study, have you experienced any physical problems that you believe are related to ketamine?
- Since your participation in the study, have you experienced any emotional or psychological problems that you believe are related to ketamine?
- Since your participation in the study, have you had any cravings for ketamine?
- Since your participation in the study, have you used ketamine outside of a research setting?
- Since your participation in the study, have you had cravings for any other illicit drug?
- Since your participation in the study, have you used any other illicit drug?
- Using a 5-point scale, where “1” is not at all acceptable, “3” is somewhat acceptable, and “5” is very acceptable, how acceptable would ketamine be to you for the treatment of your depression if ketamine were to become an approved treatment option in the future? In deciding on the acceptability of the treatment, please consider factors including perceived benefit compared to risk, convenience, and potential stigma of the treatment.